2018 AMI Online Salon

Novel Reformulation of Valsartan (ARB) for Treatment of Chronic Diabetic Wounds

Project Details

  • Artist(s):  David Rini; Baltimore, Maryland
  • Client: Peter M. Abadir, M.D. Assistant Professor of Medicine Johns Hopkins University School of Medicine
  • Copyright: © 2017 Johns Hopkins University
  • Medium / software used: Adobe Photoshop
  • Final presentation format: Print and online, Research journal
  • Primary audience: Dermatologist and researchers in wound healing

Project Description

This illustration accompanies an article I coauthored in the J. of Invest. Dermatology. Chronic wounds are among the most difficult to treat consequences of diabetes due to dysregulation of the skin renin-angiotensin system. This illustration gives an overview of the effects of a topical formulation of the angiotensin type 1 receptor blocker Valsartan on wound healing in mice. The application of 1% Valsartan gel compared with no treatment facilitated and significantly accelerated closure time and increased tensile skin strength. Valsartan treated wounds also exhibited higher mitochondrial content, better vessel wall integrity, collagen deposition, phosphorylation against decapentaplegic homologs 2, 3 and 4, alpha-smooth muscle actin, CD31, phospho-vascular endothelial growth factor receptor 2, and p42/44 mitogen-activated protein kinase.